Talecris Biotherapeutics

Share

The FDA (Food & Drug Administration) approval allows Grifols to market its physiological saline solution in 500-millimeter polypropylene bags in the U.S. hospital sector and guarantees the Group's self-sufficiency. The product is manufactured in Grifols' production plant in Las Torres de Cotillas (Murcia) Grifols' U.S. network of plasma-donation...

Talecris Biotherapeutics

 •  June 21, 2016

Hologic, Inc. (NASDAQ: HOLX) and Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) – market-leading partners committed to blood safety - announced today that the U.S. Food and Drug Administration (FDA) has approved use of the Procleix Zika virus blood screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study...

Talecris Biotherapeutics

 •  November 6, 2015

AMBAR (Alzheimer Management By Albumin Replacement) is a phase III clinical trial that explores the combination of plasma extraction and replacement with albumin (the most abundant protein in blood plasma) to stabilize Alzheimer's disease.
The intermediate results show the tolerability and safety of the treatment, meeting the necessary...

Talecris Biotherapeutics

 •  February 5, 2015

The Study is safe to continue after Investigators' Meeting and the disclosure of interim analysis in San Francisco (Dec 2014)
San Francisco, February 5, 2015: Relevant updates of the SIPPET Study have been presented during the last SIPPET Investigators' Meeting held in San Francisco in December, on the occasion of the 56th Annual Meeting of the ...